Figure 1.

In situ vaccination with CPMV generates systemic antitumor immunity in B16F10, MC38, CT26, but not in 4T1 (A) Schematic presentation of experimental setup. Two-tumor bearing mice of B16F10, MC38, CT26 had first tumor intradermal inoculated at day −7 and the distant tumor inoculated on day −4, then day −7 tumor treated with 2 weekly intratumoral injections of CPMV. (B–E) Growth curves for corresponding tumors. Two growth curves were analyzed using two-way analysis of variance, with p>0.05 as ns, p<0.05 as *, p<0.01 as **, and p<0.001 as ***. All experiments were repeated at least once with similar results and each with n=3–5 mice/group. CPMV, cowpea mosaic virus; I.D., intradermal; PBS, phosphate-buffered saline.